Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.94 1.31 +1.83%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated (CORT) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Corcept Therapeutics Incorporated (CORT) trades at a EV/EBITDA of 67.4×. Over the past ten years it has ranged from 0.0× (June 2026) to 3,420× (August 2026); the current reading is higher than 77% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 78.3× 106.33%
FY2024 38.0× 77.95%
FY2023 21.3× 44.61%
FY2022 14.8× (5.51%)
FY2021 15.6× (21.34%)
FY2020 19.8× 101.70%
FY2019 9.8× (35.75%)
FY2018 15.3× (59.11%)
FY2017 37.5× (50.64%)
FY2016 75.9× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 110× (95.40%)
Jun 2026 2,383× —
Mar 2026 0.0× —
Dec 2025 78.3× (46.02%)
43 more quarters

Against its own ten years

Low 0.0× High 3,420×
Ten-year median 19.4×
Current reading's percentile 77

EV/EBITDA against peers

Company EV/EBITDA
SYRE Spyre Therapeutics, Inc. compare n/m
ABVX Abivax SA Sponsored ADR compare n/m
PRAX Praxis Precision Medicines, Inc. compare n/m
CYTK Cytokinetics, Incorporated compare n/m
MDGL Madrigal Pharmaceuticals, Inc. compare n/m
ARWR Arrowhead Pharmaceuticals, Inc. compare n/m
KRYS Krystal Biotech, Inc. compare 34.1×
CORT Corcept Therapeutics Incorporated 67.4×
PTGX Protagonist Therapeutics, Inc. compare 145×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on CORT